FeliciaCosmanMD

Endocrinology • West Haverstraw, NY

Diabetes, Lipid Metabolism

Professor of Medicine, Columbia P&S

Join to view full profile

Dr. Cosman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Cosman's full profile

Already have an account?

Office
51 S Route 9w
Helen Hayes Hospital
West Haverstraw, NY 10993
Phone+1 845-786-4494

Fax+1 845-787-4878
Is this information wrong?

Education & Training

New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1983 - 1988
Stony Brook University Health Sciences Center School of MedicineClass of 1983

Certifications & Licensure

NY State Medical License 1985 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

Top Doctors: New York Metro Area Castle Connolly, 2002-2014
Hudson Valley Magazine Castle Connolly, 2007-2013
New York Magazine: Top Doctors Castle Connolly, 2002

Clinical Trials

Parathyroid Hormone (PTH) With Alendronate for Osteoporosis Start of enrollment: 1987 Sep 01
Completed
Phase 2
Early Effects of Parathyroid Hormone (PTH) on the Proximal Femur Start of enrollment: 2010 Aug 01
Completed
Not Applicable
The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab Start of enrollment: 2013 Aug 01
Unknown status
Phase 4

Publications & Presentations

PubMed

Oral daily PTH(1-34) tablets (EB613) in postmenopausal women with low BMD or osteoporosis: a randomized, placebo-controlled, six-month, phase 2 study.
Liana Tripto-Shkolnik, Auryan Szalat, Gloria Tsvetov, Vanessa Rouach, Chana Sternberg, Anke Hoppe, Gregory Burshtein, Hillel Galitzer, Miranda Toledano, Gil Harari, Ar...> ;Journal of Bone and Mineral Research. 2024 Apr 5
Treatment Sequence for Osteoporosis.
Langdahl, B., Cosman, F., Leder, B.> ;Endocrine Practice. 2024 Feb 2
Skin in the Game?
Felicia Cosman> ;Journal of Bone and Mineral Research. 2023 Oct 1
Romosozumab Efficacy in Postmenopausal Women With No Prior Fracture Who Fulfill Criteria for Very High Fracture Risk.
Michael R McClung, Donald Betah, Cynthia Deignan, Yifei Shi, Jen Timoshanko, Felicia Cosman> ;Endocrine Practice. 2023 Sep 1
2 citations
Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis.
Aravinda Ganapathy, Jeri W Nieves, Tony M Keaveny, Felicia Cosman> ;Bone. 2023 Feb 1
4 citations
Effect of Abaloparatide on Bone Microarchitecture Assessed by Trabecular Bone Score in Women With Osteoporosis: Post Hoc Analysis of ACTIVE and ACTIVExtend.
Felicia Cosman, Didier Hans, Enisa Shevroja, Yamei Wang, Bruce Mitlak> ;Journal of Bone and Mineral Research. 2023 Apr 1
20 citations
Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses.
Felicia Cosman, Shuang Huang, Michele McDermott, Steven R Cummings> ;Journal of Bone and Mineral Research. 2022 Nov 1
29 citations
Romosozumab and antiresorptive treatment: the importance of treatment sequence.
Felicia Cosman, David L Kendler, Bente L Langdahl, Benjamin Z Leder, E Michael Lewiecki, Akimitsu Miyauchi, Maria Rojeski, Michele McDermott, Mary K Oates, Cassandra E...> ;Osteoporosis International. 2022 Jun 1
6 citations
Effects of teriparatide and loading modality on modeling-based and remodeling-based bone formation in the human femoral neck.
Amanda M Rooney, David W Dempster, Jeri W Nieves, Hua Zhou, Mathias P G Bostrom, Felicia Cosman> ;Bone. 2022 Apr 1
40 citations
Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review.
David L. Kendler, Felicia Cosman, Robert Kees Stad, Serge Ferrari> ;Advances in Therapy. 2021 Nov 11
1 citations
Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals
Felicia Cosman, Cesar Libanati, Cynthia Deignan, Zhigang Yu, Zhenxun Wang, Serge Ferrari, Jens-Erik Beck Jensen, Pilar Peris, Francesco Bertoldo, Eric Lespessailles, E...> ;JBMR Plus. 2021 Nov 1
7 citations
Teriparatide and pelvic fracture healing: a phase 2 randomized controlled trial
Jeri W. Nieves, Felicia Cosman, Donald J. McMahon, M Redko, I Hentschel, Roger J. Bartolotta, Michael L. Loftus, J. Jacob Kazam, Jessica A. Rotman, Joseph M. Lane> ;Osteoporosis International. 2021 Aug 12
10 citations
Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture Trial
Socrates E. Papapoulos, Henry G. Bone, Felicia Cosman, David W. Dempster, Michael R. McClung, Toshitaka Nakamura, José Fernando Molina Restrepo, Mary L. Bouxsein, D Co...> ;Journal of Bone and Mineral Research. 2021 Apr 27
16 citations
Anabolic Agents for Postmenopausal Osteoporosis: How Do You Choose?
Felicia Cosman, David W. Dempster> ;Current Osteoporosis Reports. 2021 Feb 26
2 citations
Early changes in bone turnover and bone mineral density after discontinuation of long-term oral bisphosphonates: a post hoc analysis
Kenneth G. Saag, Felicia Cosman, T. J. de Villiers, Bente L. Langdahl, Boyd B. Scott, Andrew Denker, Annpey Pong, Arthur C. Santora> ;Osteoporosis International. 2021 Feb 19
16 citations
Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial
Felicia Cosman, Linda R. Peterson, Dwight A. Towler, Bruce H. Mitlak, Yamei Wang, Steven R. Cummings> ;The Journal of Clinical Endocrinology and Metabolism. 2020 Nov 1
11 citations
Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis
Paul D. Miller, John P. Bilezikian, Lorraine A. Fitzpatrick, Bruce H. Mitlak, Eugene V. McCloskey, Felicia Cosman, Henry G. Bone> ;Current Medical Research and Opinion. 2020 Oct 12
13 citations
Vertebral fracture assessment (VFA) for osteoporosis screening in US postmenopausal women: is it cost-effective?
J Yang, Felicia Cosman, Patricia W. Stone, M Li, Jeri W. Nieves> ;Osteoporosis International. 2020 Aug 11
Correction to: Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis.
N B Watts, G Hattersley, L A Fitzpatrick, Y Wang, G C Williams, P D Miller, F Cosman> ;Osteoporosis International. 2020 Aug 1
4 citations
Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend.
Susan L. Greenspan, Lorraine A. Fitzpatrick, Bruce H. Mitlak, Yamei Wang, Nicholas C. Harvey, Chad L. Deal, Felicia Cosman, Michael R. McClung> ;Menopause. 2020 Oct 1
25 citations
T-Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial
Felicia Cosman, E. Michael Lewiecki, Peter R. Ebeling, Eric Hesse, Nicola Napoli, Toshio Matsumoto, Daria B. Crittenden, Maria Rojeski, Wenjing Yang, Cesar Libanati, S...> ;Journal of Bone and Mineral Research. 2020 Jul 1
19 citations
Anabolic Therapy and Optimal Treatment Sequences for Patients With Osteoporosis at High Risk for Fracture.
Felicia Cosman> ;Endocrine Practice. 2020 Jul 1
6 citations
Loading modality and age influence teriparatide-induced bone formation in the human femoral neck.
Amanda M. Rooney, Mathias P.G. Bostrom, David W. Dempster, Jeri W. Nieves, Hua Zhou, Felicia Cosman> ;Bone. 2020 Jul 1
58 citations
Biomechanical Computed Tomography analysis (BCT) for clinical assessment of osteoporosis
Tony M. Keaveny, Bart L. Clarke, Felicia Cosman, Eric S. Orwoll, Ethel S. Siris, Sundeep Khosla, Mary L. Bouxsein> ;Osteoporosis International. 2020 Jun 1
Correction to: Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis.
N B Watts, G Hattersley, L A Fitzpatrick, Y Wang, G C Williams, P D Miller, F Cosman> ;Osteoporosis International. 2020 May 1
Join now to see all

Authored Content

Abaloparatide: An Anabolic Treatment to Reduce Fracture Risk in Postmenopausal Women with OsteoporosisOctober 2020

Press Mentions

Highlights from the ACR Review Course 2022December 6th, 2022
Conference aids2022 HighlightsOctober 27th, 2022
ACR 2020: 100+ Arthritis and Rheumatic Disease Updates Patients Must Know AboutNovember 25th, 2020
Join now to see all